fashion -WSS

fashion

author：leisure time 2025-09-03 07:42:17 - browse：2534

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： When a patient nears the end, a feared therapy can comfort

focus

WSS

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Are infertility treatments 'essential' during the Covid

Why drug prescriptions should include diagnoses

Sanders wants to replace patents with prizes for drug inventions

Scientists grapple with ethics of stem cell research

Hormonal contraceptives don’t actually treat endometriosis

focus

fashion

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

New guidelines on severe brain injury complicate already difficult decisions

State Dept. review finds Biden bears some blame for Afghanistan failures

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Hormonal contraceptives don’t actually treat endometriosis

Hepatitis C has a cure — but many Americans still lack access to it

In rare move, senator releases unverified FBI source report alleging Biden bribe

Dobbs anniversary: the lost opportunity of abortion as health care

Do masks work? RCTs can't tell us

knowledge

Sanders wants to replace patents with prizes for drug inventions

Paxlovid study fails to answer questions over benefit for broader groups

How a Boston hospital is priming medical residents to use GPT

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Donald Trump's relentless attacks on special counsel Jack Smith

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

hotspot

hotspot

focus

hotspot